Grace Therapeutics Reports $3.36 Million Net Loss and Focuses on GTx-104 Development

Grace Therapeutics, Inc. reported a net loss of $3.36 million, or $0.21 per share, for the three months ending June 30, 2025, reflecting an increase from a net loss of $2.62 million, or $0.24 per share, during the same period in 2024. The increase in net loss was primarily attributed to a significant change in the fair value of derivative warrant liabilities, which decreased by $1.88 million, alongside a reduction in interest income and a decrease in income tax benefits. However, the company managed to reduce its research and development expenses to $955,000 from $2.71 million in the previous year, largely due to the completion of its pivotal Phase 3 clinical trial for its lead product candidate, GTx-104.

In terms of financial position, Grace Therapeutics reported total assets of $69.81 million as of June 30, 2025, down from $71.99 million at the end of the previous fiscal period. The company’s cash and cash equivalents decreased to $20.01 million from $22.13 million. Current liabilities increased slightly to $2.32 million from $1.93 million, primarily due to higher trade and other payables. The company’s stockholders' equity also saw a decline, totaling $63.55 million compared to $66.61 million in the prior quarter.

Strategically, Grace Therapeutics has focused on the development of GTx-104, a novel injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH). The company submitted a New Drug Application (NDA) for GTx-104 to the FDA on June 25, 2025, following the completion of its Phase 3 STRIVE-ON trial, which demonstrated a 19% reduction in clinically significant hypotension compared to oral nimodipine. The company has also deprioritized the development of its other drug candidates, GTx-102 and GTx-101, pending additional funding or strategic partnerships.

Operationally, Grace Therapeutics has streamlined its workforce and management team as part of a strategic realignment plan initiated in May 2023. The company is now a smaller, more focused organization based in the United States, concentrating on GTx-104. As of June 30, 2025, the company had 13.83 million shares outstanding, an increase from 13.72 million shares at the end of the previous quarter. The company anticipates that its existing cash reserves will be sufficient to sustain operations for at least the next 12 months, although it will require additional capital to fund ongoing operational needs and further development of its drug candidates.